References

  1. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000.
  2. Henderson J, Knox S, Pan Y, Britt H. Changes in asthma management in Australian general practice. Prim Care Respir J 2004; 13: 138-43.
  3. Robertson C, Price D, Henry R et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175: 323-9.
  4. Gibson PG, Chang AB, Glasgow NJ et al. CICADA: Cough in Children and Adults: Diagnosis and Assessment. Australian Cough Guidelines summary statement. Med J Aust 2010; 192: 265-71.
  5. Fitzgerald D, Mellis C. Leukotriene receptor antagonists in virus-induced wheezing: evidence to date. Treat Respir Med 2006; 5: 407-17.
  6. Anderson S. How does exercise cause asthma attacks? Curr Opin Allergy Clin Immunol 2006; 6: 37-42.
  7. Merck Sharp & Dohme. Singulair (Montelukast sodium) Australian Approved Product Information.
  8. Knorr B, Franchi L, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pedriatrics 2001; 108: E48.
  9. Knorr B, Matz J, Bernstein J et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998; 279: 1181-6.
  10. Becker A, Kuznetsova O, Vermeulen J et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol 2006; 96: 800-7.
  11. Garcia Garcia M, Wahn U, Gilles L et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC Study. Pediatrics 2005; 116: 360-9.
  12. Philip G, Hustad C, Noonan G et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124: 691-6.
  13. Philip G, Hustad C, Malice M et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124: 699-706.
  14. Wallerstedt S, Brunlöf G, Sundström A, Eriksson A. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009; 18: 858-64.
  15. Volovitz B, Duenas-Meza E, Chmielewska-Szewczyk D et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma. Curr Ther Res Clin Exp 2000; 61: 490-506.
  16. Vuillermin P, South M, Robertson C. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. Cochrane Database Syst Rev 2006.
  17. Oommen A, Lambert P, Grigg J. Efficacy of a short course of parentinitiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362: 1433-8.
  18. Vuillermin P, Robertson C, Carlin J et al. Parent initiated prednisolone for acute asthma in children of school age: randomised controlled crossover trial. BMJ 2010; 340: c843.
  19. van Asperen PP, Mellis CM, Sly PD, Thoracic Society of Australia and New Zealand. Position statement. The role of corticosteroids in the management of childhood asthma. Med J Aust 2002; 176: 168-73.
  20. Peroni D, Piacentini G, Ress M et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 2002; 13: 434-7.
  21. Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, Garcia-Marcos L. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr Pulmonol 2006; 41: 222-7.
  22. Becker A, Swern A, Tozzi C et al. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 2004; 20: 1651-9.
  23. Meyer K, Arduino J, Santanello N et al. Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol 2003; 111: 757-62.
  24. Lemanske R, Mauger D, Sorkness C et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975-85.
  25. Luskin A, Bernstein A. ‘Real-world' effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90: 543-9.
  26. Sorkness C, Lemanske R, Mauger D et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119: 64-72.
  27. Zeiger R, Szefler S, Phillips B et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117: 45-52.
  28. Ostrom N, Decotiis B, Lincourt W et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147: 213-20.
  29. Jat G, Mathew J, Singh M. Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Ann Allergy Asthma Immunol 2006; 97: 397-401.
  30. Bisgaard H, Zielen S, Garcia-Garcia M et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315-22.
  31. Johnston N, Mandhane P, Dai J et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120: e702-12.
  32. Bacharier L, Phillips B, Zeiger R et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122: 1127-35.
  33. Schuh S, Willan A, Stephens D et al. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial. J Pediatr 2009; 155: 795-800.
  34. Anderson S. Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat Respir Med 2004; 3: 365-79.
  35. Kim J, Lee S, Kim H et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol 2005; 39: 162-6.
  36. Philip G, Villarán C, Pearlman D et al. Protection against exerciseinduced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44: 213-7.
  37. Stelmach I, Grzelewski T, Majak P et al. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008; 121: 383-9.
  38. Fogel R, Rosario N, Aristizabal G et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 2010; 104: 511-7.
  39. Anderson SD, Caillaud C, Brannan JD. β2-agonists and exerciseinduced asthma. Clin Rev Allergy Immunol 2006; 31: 163-80.
  40. de Benedictis F, del Giudice M, Forenza N et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006; 28: 291-5.
  41. Ni Chroinin M, Lasserson T, Greenstone I, Ducharme F. Addition of longacting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009; Issue 3.
  42. Ducharme F, Ni Chroinin M, Greenstone I, Lasserson T. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010; Issue 4.
  43. Ducharme F, Ni Chroinin M, Greenstone I, Lasserson T. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; Issue 5.
  44. Razi C, Bakirtas A, Harmanci K et al. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7-to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 767-74.
  45. Chen S, Lu K, Sun H et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 years. Pediatr Allergy Immunol 2006; 17: 49-54.
  46. Watanasomsiri A, Poachanukoon O, Vichyanond P. Efficacy of montelukast and loratadine as treatment for allergic rhinitis in children. Asian Pac J Allergy Immunol 2008; 26: 89-95.
  47. Chang A, Winter D, Acworth J. Leukotriene receptor antagonist for prolonged non-specific cough in children. Cochrane Database Syst Rev 2006; 2.
  48. van Adelsberg J, Moy J, Wei L et al. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005; 21: 971-9.
  49. Straub D, Moeller A, Minocchieri S et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005; 25: 289-94.
  50. Bisgaard H, Flores-Nunez A, Goh A et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008; 178: 854-60.